NCT04145323View on ClinicalTrials.gov

Novel Application of Indocyanine Green as a Biomarker to Identify Tissue Necrosis in Mastectomy Patients

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

September 25, 2019

Primary Completion Date

December 19, 2019

Study Completion Date

December 19, 2019

Conditions
Breast CancerNecrosis
Interventions
DIAGNOSTIC_TEST

ICG microangiography

Indocyanine Green (ICG) is a FDA approved dye which preferentially bind to exposed phospholipids in the membranes of necrotic cells, thus acting as a biomarker for necrotic tissue.

Trial Locations (1)

53792

University of Wisconsin, Madison

All Listed Sponsors
lead

University of Wisconsin, Madison

OTHER

NCT04145323 - Novel Application of Indocyanine Green as a Biomarker to Identify Tissue Necrosis in Mastectomy Patients | Biotech Hunter | Biotech Hunter